|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
EP1492511B3
(fr)
|
2002-04-09 |
2012-05-02 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
|
MXPA05007381A
(es)
|
2003-01-13 |
2006-02-10 |
Dynogen Pharmaceuticals Inc |
Metodo para el tratamiento de transtornos funcionales del intestino.
|
|
ATE487478T1
(de)
*
|
2003-01-30 |
2010-11-15 |
Lek Pharmaceuticals |
Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
|
|
KR20120058618A
(ko)
*
|
2003-01-31 |
2012-06-07 |
다이이찌 산쿄 가부시키가이샤 |
동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
|
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
JPWO2006046528A1
(ja)
*
|
2004-10-29 |
2008-05-22 |
興和株式会社 |
糸球体疾患治療剤
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
EP1850835A1
(fr)
*
|
2005-02-21 |
2007-11-07 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
|
CA2613417C
(en)
*
|
2005-06-27 |
2011-11-29 |
Daiichi Sankyo Company, Limited |
Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
|
|
DE102005031577A1
(de)
*
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
ATE548035T1
(de)
|
2005-07-11 |
2012-03-15 |
Cortria Corp |
Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
WO2009114648A1
(en)
|
2008-03-11 |
2009-09-17 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
KR101209319B1
(ko)
*
|
2008-04-29 |
2012-12-06 |
한올바이오파마주식회사 |
안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
|
|
UY32126A
(es)
*
|
2008-09-25 |
2010-04-30 |
Takeda Pharmaceutical |
Composición farmacéutica sólida
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
CN109394689A
(zh)
|
2009-05-05 |
2019-03-01 |
德州大学系统董事会 |
挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
JP6245983B2
(ja)
|
2010-08-11 |
2017-12-13 |
ドレクセル ユニバーシティ |
パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
|
|
US8435993B2
(en)
|
2010-12-07 |
2013-05-07 |
Philadelphia Health And Education Corporation |
Methods of inhibiting metastasis from cancer
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
BR112014015197A8
(pt)
|
2011-12-21 |
2017-06-13 |
Novira Therapeutics Inc |
agentes antivirais de hepatite b
|
|
IN2014DN09045A
(enExample)
|
2012-05-07 |
2015-05-22 |
Bayer Pharma AG |
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP3158995B1
(en)
|
2012-08-09 |
2018-05-23 |
Dynamis Therapeutics, Inc. |
Meglumine for reducing high triglyceride levels
|
|
WO2014107663A2
(en)
|
2013-01-07 |
2014-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cutaneous t cell lymphoma
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
ES2769893T3
(es)
|
2013-07-02 |
2020-06-29 |
Ecoplanet Env Llc |
Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20160193155A1
(en)
|
2013-09-02 |
2016-07-07 |
Sun Pharmaceutical Industries Limited |
Pulsatile-release dosage form
|
|
WO2015080943A1
(en)
|
2013-11-26 |
2015-06-04 |
Yale University |
Novel cell-penetrating compositions and methods using same
|
|
CN106029672B
(zh)
|
2013-12-06 |
2019-03-29 |
基因泰克公司 |
丝氨酸/苏氨酸激酶抑制剂
|
|
CA2933464A1
(en)
|
2013-12-09 |
2015-06-18 |
Thomas Jefferson University |
Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
|
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EP3182979B1
(en)
|
2014-08-20 |
2023-12-06 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
EP4414028A3
(en)
|
2015-05-19 |
2024-11-27 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
HK1245079A1
(zh)
|
2015-06-30 |
2018-08-24 |
纽拉德有限公司 |
新颖呼吸控制调节化合物以及其制备和使用方法
|
|
JP2018521077A
(ja)
*
|
2015-07-29 |
2018-08-02 |
タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ |
糖尿病性腎症を治療するためのｐｄｅ４阻害剤
|
|
EP3368505B1
(en)
|
2015-10-28 |
2023-02-22 |
Yale University |
Quinoline amides and methods of using same
|
|
EP3377105A4
(en)
|
2015-11-20 |
2019-04-24 |
Yale University |
COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
|
WO2018026764A1
(en)
|
2016-08-01 |
2018-02-08 |
University Of Rochester |
Nanoparticles for controlled release of anti-biofilm agents and methods of use
|
|
CA3032467A1
(en)
|
2016-08-05 |
2018-02-08 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
ES2896487T3
(es)
|
2016-09-01 |
2022-02-24 |
Mebias Discovery Llc |
Derivados de urea sustituidos para el tratamiento del dolor
|
|
SG11201902944TA
(en)
|
2016-11-07 |
2019-05-30 |
Arbutus Biopharma Corp |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
WO2018136766A1
(en)
|
2017-01-19 |
2018-07-26 |
Temple University-Of The Commonwealth System Of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|
|
WO2019023621A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
|
|
EP3679063A4
(en)
|
2017-09-08 |
2021-06-02 |
The Regents of The University of Colorado, A Body Corporate |
COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER
|
|
CN111818929A
(zh)
|
2017-11-27 |
2020-10-23 |
由卫生与公众服务部部长代表的美利坚合众国 |
用于治疗和/或预防牙周疾病的化合物、组合物和方法
|
|
AU2018388577B2
(en)
|
2017-12-18 |
2024-06-06 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
|
CA3085941A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
CA3097737A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
TW201944989A
(zh)
|
2018-01-24 |
2019-12-01 |
洛克斐勒大學 |
抗菌化合物、其組成物及使用其之方法
|
|
US11897942B2
(en)
|
2018-05-25 |
2024-02-13 |
Temple University—Of the Commonwealth System of Higher Education |
Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
|
|
JP2021525269A
(ja)
|
2018-05-29 |
2021-09-24 |
セルシィ セラピューティクス，インコーポレーテッド |
疼痛処置のための化合物、それを含む組成物及びそれを使用する方法
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CA3109798A1
(en)
|
2018-08-17 |
2020-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of acute lung injury
|
|
CA3113377A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
|
WO2020081762A1
(en)
|
2018-10-19 |
2020-04-23 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
MX2021008966A
(es)
|
2019-01-30 |
2021-11-04 |
Sanifit Therapeutics S A |
Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
CA3136665A1
(en)
|
2019-04-12 |
2020-10-15 |
Sdg, Inc. |
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
EP3965792A4
(en)
|
2019-05-09 |
2023-01-18 |
The Feinstein Institutes for Medical Research |
HMGB1 ANTAGONIST
|
|
JP2022538767A
(ja)
|
2019-06-12 |
2022-09-06 |
ザ ウィスター インスティテュート |
アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
WO2021252549A1
(en)
|
2020-06-09 |
2021-12-16 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
CN116546984A
(zh)
|
2020-09-28 |
2023-08-04 |
耶鲁大学 |
5-ht2a受体的选择性激动剂及其使用方法
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
AU2023313374A1
(en)
|
2022-07-29 |
2025-02-13 |
Vifor (International) Ltd. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|
|
JP2026513019A
(ja)
|
2023-02-03 |
2026-04-22 |
トリス・フアルマ・インコーポレーテツド |
１晩１回の低ナトリウムオキシベート組成物
|
|
TW202513071A
(zh)
|
2023-08-14 |
2025-04-01 |
以色列商琉璃藥品 (1991) 有限公司 |
Gal475組合物及其使用方法
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|